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comprehensive literature review, with expert panel judgment,
informed the selection of criteria (and their relative weighting)
for the pharmacotherapeutic evaluation. The resultant scoring
system was circulated (in questionnaire format) to prescribers
and stakeholders for comment. Based on statistical analysis of
the latter survey results, the ﬁnal scoring system was developed.
Drug entities which exceeded the evidence threshold score were
entered into a tendering process with pharmaceutical suppliers.
Product lines submitted as a result of the tendering process were
sequentially entered into the second and third phases of the
STEPS process (safety/risk assessment; budget impact analysis).
RESULTS: Three drug entities (from the 5 currently available in
the UK) exceeded the evidence threshold and 29 from 39 sub-
mitted product lines, containing these drug entities, satisﬁed the
safety evaluation/risk assessment criteria. Two product lines,
each containing a different drug entity, were selected for formu-
lary inclusion as a result of the budget impact analysis. The esti-
mated annual cost savings for statins as a result of this selection
process (based on estimated annual usage in Deﬁned Daily
Doses) in this health board, was 40%. CONCLUSION: The
STEPS model has a signiﬁcant contribution to make in contain-
ing statin costs while retaining the most therapeutically appro-
priate agents.
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OBJECTIVES: The purpose of the study is to evaluate the impact
of a tablet splitting program in a large pharmacy beneﬁt man-
agement organization on the costs and utilization of prescription
drugs. METHODS: Using a retrospective cohort study design,
prescription records from January 1, 2005 to June 30, 2005 were
obtained from a pharmacy claims database. Three study cohorts-
voluntary, mandatory, and control cohort were created based on
the enrollment status in the tablet splitting program. The number
of prescriptions dispensed, the total costs and savings per pre-
scription were analyzed and compared for the study drugs
Lexapro, Lipitor, and Zoloft. RESULTS: A total of 606,068 pre-
scriptions, 594,825 in the control, 5226 in the mandatory and
6017 in the voluntary cohort were included. Total cost savings
were obtained by subtracting the difference in cost/days supply
between drugs in the control group and each active treatment
group. Total cost savings are at $179,575.85 and $74,119.53 for
the mandatory and the voluntary cohort respectively after adjust-
ing for the operation costs and subtracting the costs from the
treatment cohorts. An average per prescription cost saving of
$34.36 for the mandatory and $12.31 for the voluntary program
was realized for the three drugs studied. CONCLUSIONS: A
tablet splitting program has been shown to produce signiﬁcant
savings, $34.36 and $12.31 per prescription for the health plan
enrolled in the mandatory and voluntary programs respectively.
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OBJECTIVES: The purpose of this study was to perform a lon-
gitudinal content analysis to assess trends in contributed research
papers presented at ISPOR Annual Meetings and European Con-
gresses from 1998 through 2005 as available in the ISPOR
Research Digest at www.ispor.org, as well as to assess research
quality indicators. METHODS: The database of 5852 con-
tributed presentations at the ISPOR meetings from 1998 through
2005 were analyzed for trends and quality indicators. Trends
were evaluated for outcomes assessed (clinical, economic,
patient-reported outcomes), and types of health policy and dis-
eases studied. Quality indicators were deﬁned as abstracts
including “study perspective, “discounting”, or “ statistical con-
siderations (“conﬁdence interval”, “standard deviation”,
“mean/median”, “sensitivity analysis”). RESULTS: ISPOR held
16 international meetings during 1998–2005. The annual
number of contributed research presentations increased from
270 to 1248 for an eight-year total of 5852 with all topics and
disease categories increasing over time. The major topic areas
covered were cost (42%), patient-reported outcomes including
methods (23%), health policy (23%), methods and concepts
(10%), and clinical outcomes evaluations (6.4%). The top 
four diseases (4992 disease-speciﬁed papers) were neurologi-
cal/mental health (18.5%), cardiovascular (17%), cancer (9%),
and infectious diseases (10%). With respect to quality indicators,
of the abstracts analyzed, a study perspective was mentioned in
18% (37% cost studies, & all others ~4% each); discounting in
8% (16% cost studies & all others <2% each). For statistical
considerations, the percent mentioning mean, median, standard-
deviation, conﬁdence intervals, or sensitivity analysis (12%), was
41%. Overall, the percent of abstracts with these quality indi-
cators generally increased over the study period. CONCLU-
SION: The number of papers has increased over the study period
for multiple topics and diseases. Although the general quality of
papers, as considered in this analysis, was increasing, the percent
of papers that include these quality indicators needs further eval-
uation & improvement.
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OBJECTIVE: The aim of the study to calculate the Lorenz con-
centration curves and Gini coefﬁcient of health expenditures in
Hungary. METHODS: Data derived from the ﬁnancial database
of the Hungarian National Health Insurance Fund Administra-
tion, covering the period 2000–2004. The Hungarian health care
ﬁnancing system based on a regular patient level data reporting
system which allows us to calculate the cumulative frequency dis-
tributions of health expenditures. In each type of care we put the
patients into 100 percentile group ranked by the health expen-
ditures. RESULTS: The top quadrant (top 25%) of the patients
(with highest health expenditures) received different portion of
health expenditures (2004): 72.4% in out-patient care, 64.1%
in in-patient care, 67.3% in chronic care, 56.3% in CT/MRI
examinations, 56.2% in home care, 46.1% in renal dialysis,
83.8% in drug reimbursement, 83.6% in medical devices reim-
bursement. The visual Lorenz curves are presented for each type
of care mentioned earlier and for the ﬁve years between
20000–2004. There was not any signiﬁcant time trend within the
same type of care. We found the following Gini coefﬁcients
(2004): out-patient care: 0.6352, in-patient care: 0.5278, chronic
care: 0.5624, CT/MRI examinations: 0.4459, home care:
0.4319, renal dialysis: 0.4251, drug reimbursement: 0.7444,
medical devices reimbursement: 0.7480. We found signiﬁcant
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changes between 2000–2004 in inpatient care, home care,
CT/MRI examinations. CONCLUSIONS: The budgets of drug
and medical devices reimbursement are highly concentrated
while the distribution of renal dialysis expenditures was the most
linear. Gini coefﬁcient of inpatient care, home care and CT/MRI
examinations showed signiﬁcant time trend.
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OBJECTIVES: Prescription drug prices between Canadian and
US on-line pharmacies were studied over a 6-month period.
METHODS: Prices for 28 popular brand name medications were
collected from eight Canadian and ﬁve US on-line pharmacies
weekly for six months. Prices were compared between Canadian
and US on-line pharmacies, and price changes were monitored
each week. RESULTS: During the study period, purchasing from
Canadian on-line pharmacies would save consumers >$1.00 per
unit for 12 drugs (42.9%). Savings were demonstrated in two
drugs if purchased from US on-line pharmacies: sildenaﬁl 25mg
($2.06/unit) and amlodipine 10mg ($0.02/unit). Average price
increases from the ﬁrst to the last week of the 6-month period
were greater from Canadian on-line pharmacies ($0.10/unit)
compared to the US ($0.07/unit). From Canadian on-line phar-
macies, prices from all the medications increased during the
study period except one, which stayed the same. The two drugs
with the greatest price increases were alendronate 70mg
($1.04/unit) and sildenaﬁl 25mg ($0.45/unit). From US on-line
pharmacies, nine drug prices decreased during the study period,
four remained the same, and 15 increased. The greatest price
increases were for alendronate 70mg ($0.62/unit) and olanzap-
ine 10mg ($0.41/unit). Consumer savings from purchasing
Canadian on-line drugs decreased from the ﬁrst to the last week
of the 6-month period for 17 medications (60.7%), with the
greatest decrease in savings being for 100 units of gabapentin
300mg (19.4% decrease) and sertraline 100mg (15.1%
decrease). CONCLUSIONS: When 100% of prescription drug
payments are out-of-pocket, consumers usually save money
when buying from Canadian on-line pharmacies. Although
prices were lower using these pharmacies, price increases over
the study period were greater. In order to get the best price for
medications purchased on-line, one would need to compare
prices from multiple pharmacies in Canada and the US for each
prescription drug over a period of time.
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OBJECTIVES: Specialty pharmaceuticals account for a signiﬁ-
cant and growing proportion of health plans’ pharmacy budget.
This research examined how insurance type, deﬁned as tradi-
tional (TRAD), managed care (MC) or preferred provider orga-
nization (PPO), affects a plan’s annual per enrollee and per
patient expenditures on specialty pharmaceuticals. METHODS:
Three years (2002–2004) of outpatient specialty pharmaceuticals
claims data, extracted based on a predeﬁned list of HCPCS, CPT
and NDC codes, from 15 BlueCross and BlueShield plans were
used to construct ﬁxed effect panel data models. Because of
potential adverse selection and dual insurance coverage in the
65+ age group, this study focused on the under 65 age group.
Covariates included in the models were plan, year, insurance type
and drug categories. Model parameters were estimated using
generalized estimating equations (GEE). RESULTS: Plan and
drug categories were signiﬁcant covariates in models estimating
per enrollee as well as per patient expenditures. Adjusted per
enrollee expenditure increased 39.6% from 2002 to 2003 and
27.8% from 2003 to 2004. Per enrollee expenditure was 20.3%
(p = 0.0215, 95% CI: 3.3–34.3%) lower in MC and 39.5% (p
< 0.001, 95% CI: 27.7–49.3%) lower in PPO than TRAD plans.
PPO plans had 24.1% (p = 0.015, 95% CI: 10.0–35.9%) lower
per enrollee expenditure than MC plans. Adjusted per patient
expenditure increased 15.3% from 2002 to 2003 and 10.8%
from 2003 to 2004. Insurance type was not signiﬁcantly 
associated with per patient expenditure. CONCLUSIONS: A
plan’s per enrollee expenditure on outpatient specialty pharma-
ceuticals differed across insurance type. TRAD had the highest
per enrollee expenditure, followed by MC and then PPO 
plans. However, insurance type did not signiﬁcantly affect 
a health plan’s per patient expenditure on outpatient 
specialty pharmaceuticals.
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OBJECTIVES: To estimate the return on investment (ROI) asso-
ciated with database integration technology enabling automated
bidirectional sharing of patient data between a hospice and
hospice pharmacy provider. METHODS: ROI was calculated as
total direct savings (TDS) and payback period in years (PPY).
Formula inputs were costs of implementing a bidirectional 
interface between the pharmacy and hospice, and costs of 
telephone/fax transmission of demographic and medication data.
The net present value (NPV) adjusted for inﬂation was used to
forecast future cash inﬂows across three years. RESULTS: Esti-
mated annual savings for unidirectional interface were $7500
and bidirectional savings were $22,500 for a hospice admitting
300 patients/month, assuming $50,000 nurse salary. Hospice
nurses were assumed to use wireless phones for transmission of
patient admission data. Replacement of voice with interface
resulted in estimated savings of $1800 annually. Telephone
savings for medication proﬁle data transmission yielded $1620
annually. After summing the immediate gains of recovered time
inefﬁciencies and reduced telephone usage, implementation of a
pharmacy/hospice interface resulted in TDS of $33,420 annually.
The discounted or investment yield rate utilized was 10%. There-
fore, while projected total net savings generated by a phar-
macy/hospice interface across 3 years equaled $100,260, the
total NPV, reﬂecting the time value of money, was $84,596. The
annual ROI represented by the NPV of the pharmacy/hospice
interface was 1127.94%. The PPY (breakeven analysis) in which
the ﬁnancial beneﬁts exceed the initial investment would be
reached in 0.27 years. CONCLUSIONS: “Low-tech” bias and
lack of capital for investment in technology have contributed to
a lag in adoption of technological innovations in hospice. Pro-
jected ROI for automated data sharing via interface suggested
considerable decrease in administrative costs. Hospice adminis-
trators could apply the formulas used in this study with their
unique data to forecast ROI in their settings.
